You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

untreated%20indolent%20Non-Hodgkin's%20Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)

Active, not recruiting
  • Non Hodgkin's Lymphoma
  • Sacramento, California
  • +1 more
Nov 15, 2021

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 6, 2022

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Indolent Non-Hodgkin Lymphoma Trial in München (Ibrutinib, GA 101)

Active, not recruiting
  • Indolent Non-Hodgkin Lymphoma
  • München, Bavaria, Germany
    Klinikum der Universität München
May 6, 2021

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 13, 2022

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • EO2463
  • +2 more
  • Boston, Massachusetts
  • +9 more
Jul 26, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)

Completed
  • Waldenstrom Macroglobulinemia
  • Washington, District of Columbia
  • +3 more
Oct 19, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent

Completed
Has Results
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 28, 2021

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

    Withdrawn
    • Recurrent Follicular Lymphoma
    • +8 more
    • (no location specified)
    Jun 2, 2022

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

    Active, not recruiting
    • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
    • Nagoya, Aichi, Japan
    • +5 more
    Dec 10, 2021

    Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +8 more
    • Miami, Florida
    • +2 more
    Apr 21, 2022